Amadeus Capital Partners is an investor backing trailblazers solving hard problems across intelligence, human, and planet technology areas from seed to growth stages.
The seed round was led by Parkwalk Advisors and includes backing from Amadeus Capital Partners, Crista Galli, RCA, and Oxbridge Angels to fund the market launch of the CUE1 device.
"We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials."
The seed round was backed by Amadeus Capital Partners, Delin Ventures and Kindred Capital to fund the commercial launch of its manufacturing technology.
"Hundreds of clinical trials and a few recently marketed products have shown the revolutionary potential of CGTs. But this potential will never be realised unless we can remove the current bottleneck around scalable manufacturing. Ori Biotech has developed an innovative platform technology to facilitate scalable manufacturing that could eventually enable millions of patients to get access to the next generation of personalised medicines,"
The financing round was led by Atomico with participation from several returning and new investors.
"The size of this Series B financing, especially this quickly after our Series A round last year, is an endorsement of the value of our platform and the pace at which we have developed. It allows us to scale our impact with the launch of our Rare Treatment Accelerator programme and to progress into clinical trials."
The Series B round was led by Kureha Corporation and will accelerate commercial rollout and market expansion.
"We’re delighted to welcome our new corporate and VC investors from Japan and China, as well as having the continued strong support of our existing investors, who together form a world-class group that will help scale CTT quickly to exploit the market opportunity for its technology. CTT has grown rapidly over the last several years, and we’re looking forward to being able to continue executing on our growth plan and sharpening our commercialization focus within the consumer electronics, automotive and industrial markets. The partners we have and the injection of new capital means we can expect to enable our customers to begin rolling out the technology at scale in the near future."
Parkwalk led the Series A financing to support product development and commercialisation.
"This funding marks the start of the next phase in Paragraf’s growth. I am extremely proud of the young team at Paragraf who have collectively delivered the early strategy milestones with great skill. This next phase will allow Paragraf to make these truly game-changing technologies a reality. Paragraf is continually seeking like-minded collaborative development, production and commercial partners to accelerate the delivery of the many exciting electronics technology opportunities graphene has to offer."
